96 related articles for article (PubMed ID: 7579012)
1. Lymphocyte ultrastructure in patients with multiple sclerosis.
Djaldetti R; Achiron A; Ziv I; Djaldetti M
Biomed Pharmacother; 1995; 49(6):300-3. PubMed ID: 7579012
[TBL] [Abstract][Full Text] [Related]
2. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
[TBL] [Abstract][Full Text] [Related]
3. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
5. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y
Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
[TBL] [Abstract][Full Text] [Related]
7. [Intravenous immunoglobulins for relapsing-remitting multiple sclerosis after failure of treatment with other immuno-modulators].
Lebrun C; Ghetau G; Bourg V; Chanalet S; Dumas S; Chatel M
Rev Neurol (Paris); 2003 Jul; 159(6-7 Pt 1):648-51. PubMed ID: 12910072
[TBL] [Abstract][Full Text] [Related]
8. [Intravenous immunoglobulins (IVIg) in the treatment of multiple sclerosis].
Achiron A; Miron S
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S41-4. PubMed ID: 10896988
[TBL] [Abstract][Full Text] [Related]
9. [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial].
Fernández O; Antigüedad A; Arbizu T; Burgués S; Capdevila A; de Castro P; Correa de Sá JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X; Zarranz JJ
Rev Neurol; 1999 Dec 16-31; 29(12):1093-9. PubMed ID: 10652728
[TBL] [Abstract][Full Text] [Related]
10. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
11. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Ostberg A; Pittas F; Taylor B
Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
[TBL] [Abstract][Full Text] [Related]
12. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
13. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.
Sørensen PS
Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
[TBL] [Abstract][Full Text] [Related]
15. Expression of Fas antigen on T cell subpopulations in peripheral blood of patients with relapsing-remitting multiple sclerosis.
Bilińska M; Frydecka I; Podemski R; Teodorowska R; Gruszka E
Med Sci Monit; 2001; 7(2):251-5. PubMed ID: 11257731
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab use in pediatric multiple sclerosis.
Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
[TBL] [Abstract][Full Text] [Related]
17. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
Yushchenko M; Mäder M; Elitok E; Bitsch A; Dressel A; Tumani H; Bogumil T; Kitze B; Poser S; Weber F
J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607
[TBL] [Abstract][Full Text] [Related]
18. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
19. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis.
Calabrese M; De Stefano N; Atzori M; Bernardi V; Mattisi I; Barachino L; Morra A; Rinaldi L; Romualdi C; Perini P; Battistin L; Gallo P
Arch Neurol; 2007 Oct; 64(10):1416-22. PubMed ID: 17923625
[TBL] [Abstract][Full Text] [Related]
20. Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study.
Calabrese M; Filippi M; Rovaris M; Mattisi I; Bernardi V; Atzori M; Favaretto A; Barachino L; Rinaldi L; Romualdi C; Perini P; Gallo P
Neuroimage; 2008 Oct; 42(4):1324-8. PubMed ID: 18652903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
